ACTRN12610000432011
Not yet recruiting
Phase 4
A randomised controlled trial of atomoxetine vs placebo for attentional lapses in adults with attention deficit hyperactivity disorder (ADHD)
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- The University of Queensland
- Enrollment
- 68
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged at least 18 years
- •Diagnosis of ADHD
Exclusion Criteria
- •1\. Current or past diagnosis of psychotic disorders, pervasive development disorders, intellectual impairment,
- •2\. History of serious neurologic illnesses including stroke, brain tumours, head trauma, multiple sclerosis, epilepsy, movement disorders or migraine in treatment
- •3\. drug dependency on alcohol or illicit substances
- •4\. Pregnancy or breast feeding
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
Study of the effect of Atomoxetine on cognitive symptoms in patients with schizophreniaIRCT20101130005280N31Mashhad University of Medical Sciences42
Completed
Not Applicable
Atomoxetine for attention deficit hyperactivity disorder (ADHD) in children with special educational needsAttention deficit hyperactivity disorder (ADHD), mental retardation (intellectual disability)Mental and Behavioural DisordersHyperkinetic disordersISRCTN25691213King's College London (UK)40
Completed
Phase 4
Comparison of Atomoxetine and Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD) and/or Reading Disorder (RD)Attention Deficit Hyperactivity DisorderReading DisorderNCT00191906Eli Lilly and Company121
Active, not recruiting
Not Applicable
An Open-Label Study of the Efficacy of Atomoxetine Hydrochloride on Quality of Life of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder with or without comorbid conditions - NDChild or adolescent patients with Attention-Deficit/ Hyperactivity Disorder ADHDMedDRA version: 6.1Level: PTClassification code 10003736EUCTR2005-005701-32-ITELI LILLY300
Recruiting
Phase 2
Effectiveness of Atomoxetine treatment for methamphetamine use disorderOther stimulants dependence syndrome.Dependence syndrome: A cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and that typically include a strong desire to take the drug, difficulties in controlling its use, persisting in its use despiteF15.24IRCT2017070234844N1Tehran University of Medical Sciences (TUMS), Vice-chancellor for Research90